Project Grant R16AI184345
- This federal Project Grant award of $214,742 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to identify and characterize Toxoplasma gondii (T. gondii) proteins that facilitate the parasite's ability to cross the placental barrier and cause congenital infection. The research team at Texas A&M University will use innovative in vitro models and pregnant guinea pig studies to test the role...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 4-year, $2,456,732 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine in the Bronx, NY. The grant supports research to understand the mechanisms behind Toxoplasma gondii, an opportunistic pathogen that causes neurological infection in people living with HIV/AIDS and results in high morbidity and mortality. The research focuses on elucidating the...
- This Project Grant award of $426,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the functions of two proteins, PEX4 and PEX22, in apicomplexan parasites. Apicomplexan parasites, such as Plasmodium falciparum (malaria) and Toxoplasma gondii (opportunistic infections), have major impacts on human health. The research team at Boston College will explore how...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $603,601 to the Regents of the University of Michigan to develop novel protease inhibitors that can eliminate chronic Toxoplasma gondii infection in the retina. The goal is to establish a safe and effective 2-week treatment to prevent recurrent ocular toxoplasmosis, a leading cause of infectious posterior...
- This $563,513 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by Arizona State University on the patterning, growth, and maturation of cortical microtubules in Toxoplasma, a unicellular parasite that causes diseases like toxoplasmosis. The project aims to explore the initiation of microtubule patterning (Aim 1) and the growth and maturation of the microtubule array (Aim 2) in these...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $556,510 to The Trustees of the University of Pennsylvania to conduct research focused on understanding the molecular mechanisms and evolutionary aspects of the rhoptry secretion system in unicellular eukaryotes, including apicomplexan parasites and non-pathogenic ciliates. The research program aims to unravel the...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $435,875 to the University of California, Merced (UC Merced) to investigate the role of the NFKBID gene in humoral immunity to the parasite Toxoplasma gondii. The research aims to understand how the NFKBID-encoded protein IKBNS mediates protective antibody responses, with a focus on the function of NFKBID in CD4 T...
- This $847,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) supports research to investigate the protective roles of the CD180 and NOD1 pathogen-recognition molecules in the immune response to cerebral Toxoplasma gondii infection. The research aims to elucidate how these molecules in the brain contribute to the rapid detection of Toxoplasma tachyzoites and activation of...
- This federal Project Grant award, totaling $133,693, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award is funding research conducted by Fundacion Instituto De Investigaciones Biotecnologicas, a non-profit research institute in Buenos Aires, Argentina, to investigate the role of an unusual variant nucleosome in the life cycle of the parasite Toxoplasma gondii. The research aims to...
- This federal Project Grant award of $1,731,364.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Kentucky Research Foundation. The grant supports research to understand the role of microglial interferon-gamma (IFN-γ) production in coordinating both innate and T cell-mediated protective immunity in the brain to prevent reactivation of Toxoplasma gondii infection and the...
ROLE OF REACTIVE OXYGEN SPECIES IN CONTROLLING T. GONDII ACUTE INFECTION - PROJECT SUMMARY / ABSTRACT TOXOPLASMA GONDII IS A PROTOZOAN PARASITE THAT INFECTS APPROXIMATELY ONE-THIRD OF HUMANS WORLDWIDE AND CAUSES TOXOPLASMOSIS, A NEGLECTED INFECTIOUS DISEASE IN THE UNITED STATES. ALTHOUGH MOST HUMAN INFECTIONS ARE MILD OR ASYMPTOMATIC, T. GONDII INFECTION CAN RESULT IN LIFE-THREATENING DISEASE IN IMMUNOCOMPROMISED INDIVIDUALS AND IN THE DEVELOPING FETUS DUE TO CONGENITAL INFECTION, UNDERSCORING THE ROLE OF THE HOST IMMUNE SYSTEM IN CONTROLLING THE PARASITE. ALTHOUGH IT IS WELL DOCUMENTED THAT NEUTROPHILS INFILTRATE THE SITE OF ACUTE T. GONDII INFECTION, THERE IS LIMITED UNDERSTANDING OF HOW HUMAN NEUTROPHILS RESPOND TO T. GONDII. AS THERAPEUTIC STRATEGIES ARE STILL LIMITED, AND NO VACCINE IS AVAILABLE, THERE IS A CRITICAL NEED TO UNCOVER THE PERTINENT INNATE IMMUNE RESPONSES TO T. GONDII INFECTION. NEUTROPHILS CONTROL INFECTIOUS PATHOGENS BY A VARIETY OF MECHANISMS, INCLUDING THE RELEASE OF REACTIVE OXYGEN SPECIES (ROS). THE PRODUCTION OF ROS HAS BEEN DEMONSTRATED IN T. GONDII-INFECTED NEUTROPHILS; HOWEVER, THE CELLULAR AND MOLECULAR MECHANISMS INVOLVED IN THESE PROCESSES AND THEIR CONTRIBUTION TO PARASITE KILLING ARE UNKNOWN. IN THE CURRENT PROPOSAL, WE WILL: I) DETERMINE THE CELLULAR EVENTS REQUIRED TO INDUCE ROS IN T. GONDII-INFECTED NEUTROPHILS, II) DETERMINE WHICH RECEPTORS ARE ASSOCIATED WITH T. GONDII RECOGNITION AND ROS PRODUCTION, III) DETERMINE WHETHER T. GONDII-INDUCED ROS IS MEDIATED BY THE NOX2- DEPENDENT OR NOX2-INDEPENDENT (MITOCHONDRIAL) PATHWAY IN NEUTROPHILS, AND IV) DETERMINE WHETHER ROS AND PHAGOSOME MATURATION CONTRIBUTE TO NEUTROPHIL-MEDIATED T. GONDII KILLING. WE WILL USE PRIMARILY THE CELL LINE HL- 60, WHICH IS A DEVELOPMENTAL PRECURSOR OF NEUTROPHILS AND CAN BE DIFFERENTIATED INTO NEUTROPHIL-LIKE CELLS (NLCS) FOR FUNCTIONAL TESTS. THIS IS A SUITABLE MODEL THAT ALLOWS US TO DECIPHER SIGNALING PATHWAYS BY USING GENETIC LOSS- OF-FUNCTION EXPERIMENTS. ADDITIONALLY, WE WILL CONFIRM OUR CENTRAL FINDINGS IN PRIMARY HUMAN NEUTROPHILS ISOLATED FROM HEALTHY BLOOD DONORS. OUR PRELIMINARY DATA ON NLCS AND PRIMARY HUMAN NEUTROPHILS HAVE INDICATED THAT THESE CELLS PRODUCE ROS AND KILL PHAGOCYTOSED PARASITES. THE RATIONALE FOR THIS PROJECT IS THE RELEVANCE OF UNDERSTANDING THE VERY EARLY IMMUNE EVENTS THAT AFFECT THE PROGRESSION OF THE HOST RESPONSE AND THE DISEASE. COMPLETION OF THESE STUDIES IS THEREFORE EXPECTED TO HAVE A SIGNIFICANT IMPACT BY PROVIDING FOUNDATIONAL KNOWLEDGE THAT CAN AFFECT OUR ABILITY TO DEVELOP THERAPEUTICS, THUS CONTROLLING T. GONDII SPREAD TO SITES SUCH AS THE HEART AND THE BRAIN AND ATTENUATING DISEASE PATHOGENESIS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $182.5k | 7/3/25 | ||
| Not listed | $176.5k | 7/24/24 |